Consistent with previous WHO guidelines, the new CAB-LA guidelines are based on a public health approach that considers effectiveness, acceptability, feasibility and resource needs across a variety of settings.
13402
该指南旨在促进长效注射用卡博特韦交付和急需的业务研究，以解决实施和安全性问题。
The guidelines are designed to facilitate CAB-LA delivery and the operational research which is urgently needed to address implementation and safety issues.
13403
这将为决定如何成功提供和扩大长效注射用卡博特韦的使用提供依据。
These will inform decisions on how to successfully provide and scale up CAB-LA.
The guidelines highlight criticalresearch gaps, including issues relating to HIV drug resistance, HIV testing, service delivery models, resource requirements, safety in pregnancy and breastfeeding, and provision of CAB-LA in geographies and for populations not included in the trials.
13405
指南还指出，年轻人和重点人群在获得当前暴露前预防服务时经常遇到挑战。
The guidelines also note that young people and key populationsoften experience challenges in accessing current PrEP services.
13406
社区必须参与制定和提供有效、可接受的艾滋病毒预防服务并支持人们的选择。
Communities must be involved in developing and delivering HIV prevention services that are effective, acceptable and support choice.
13407
关于RTS,S疟疾疫苗的问答
Q&A on RTS,S malaria vaccine
13408
2023年4月19日 | 问答
19 April 2023 | Q&A
13409
什么是RTS,S/AS01疟疾疫苗？
What is the RTS,S/AS01 malaria vaccine?
13410
RTS,S/AS01(RTS,S)是针对恶性疟原虫(全球最致命且在非洲最流行的疟疾寄生虫)的疫苗。
RTS,S/AS01 (RTS,S) is a vaccine that acts against Plasmodium falciparum , the deadliest malaria parasite globally and the most prevalent in Africa.